SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Yaima Tundidor, Claudia Patricia García-Hernández, Amaury Pupo, Yanelys Cabrera Infante, Gertrudis Rojas, Delineating the functional map of the interaction between nimotuzumab and the epidermal growth factor receptor, mAbs, 2014, 6, 4

    CrossRef

  2. 2
    Jian Meng, Qian-ping Gu, Qing-fei Meng, Jie Zhang, Zhi-ping Li, Ya-meng Si, Wei Guo, Qian-wei Zhuang, Efficacy of Nimotuzumab Combined with Docetaxel–Cisplatin–Fluorouracil Regimen in Treatment of Advanced Oral Carcinoma, Cell Biochemistry and Biophysics, 2014, 68, 1, 181

    CrossRef

  3. 3
    Yu Du, Noah D. Peyser, Jennifer R. Grandis, Integration of molecular targeted therapy with radiation in head and neck cancer, Pharmacology & Therapeutics, 2014, 142, 1, 88

    CrossRef

  4. 4
    Maria Teresa Solomon, Nederlay Miranda, Eugenia Jorrín, Ivonne Chon, Jorge Juan Marinello, José Alert, Patricia Lorenzo-Luaces, Tania Crombet, Nimotuzumab in combination with radiotherapy in high grade glioma patients: A single institution experience, Cancer Biology & Therapy, 2014, 15, 5, 504

    CrossRef

  5. 5
    Ning-Yi Ma, Xu-Wei Cai, Xiao-Long Fu, Yuan Li, Xiao-Yan Zhou, Xiang-Hua Wu, Xi-Chun Hu, Min Fan, Jia-Qing Xiang, Ya-Wei Zhang, Hai-Quan Chen, Song-Tao Lai, Guo-Liang Jiang, Kuai-Le Zhao, Safety and efficacy of nimotuzumab in combination with radiotherapy for patients with squamous cell carcinoma of the esophagus, International Journal of Clinical Oncology, 2014, 19, 2, 297

    CrossRef

  6. 6
    Wataru Okamoto, Takayuki Yoshino, Toshiaki Takahashi, Isamu Okamoto, Shinya Ueda, Asuka Tsuya, Narikazu Boku, Kazuto Nishio, Masahiro Fukuoka, Nobuyuki Yamamoto, Kazuhiko Nakagawa, A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors, Cancer Chemotherapy and Pharmacology, 2013, 72, 5, 1063

    CrossRef

  7. 7
    Meilyn Rodríguez, Lincidio Pérez, Jorge V. Gavilondo, Greta Garrido, Mónica Bequet-Romero, Ignacio Hernández, Vivian Huerta, Gleysin Cabrera, Marlene Pérez, Osmani Ramos, René Leyva, Mariela León, Pedro Luis Ramos, Ada Triguero, Abel Hernández, Belinda Sánchez, Marta Ayala, Jeny Soto, Ernesto González, Osmani Mendoza, Kenia Tiel, Merardo Pujol, Comparative in vitro and experimental in vivo studies of the anti–epidermal growth factor receptor antibody nimotuzumab and its aglycosylated form produced in transgenic tobacco plants, Plant Biotechnology Journal, 2013, 11, 1
  8. 8
    Charles E. Rengifo, Rancés Blanco, Damián Blanco, Mercedes Cedeño, Milagros Frómeta, Enrique Rengifo Calzado, Immunohistochemical Characterization of Three Monoclonal Antibodies Raised against the Epidermal Growth Factor and Its Receptor in Non-Small-Cell Lung Cancer: Their Potential Use in the Selection of Patients for Immunotherapy, Journal of Biomarkers, 2013, 2013, 1

    CrossRef

  9. 9
    Teresa Troiani, Silvia Zappavigna, Erika Martinelli, Santolo R. Addeo, Paola Stiuso, Fortunato Ciardiello, Michele Caraglia, Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance, Expert Opinion on Biological Therapy, 2013, 13, 2, 241

    CrossRef

  10. 10
    Pavel Barta, Alice Laznickova, Milan Laznicek, Denis Rolando Beckford Vera, Milos Beran, Preclinical evaluation of radiolabelled nimotuzumab, a promising monoclonal antibody targeting the epidermal growth factor receptor, Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 5
  11. 11
    Kuai-le Zhao, Xi-chun Hu, Xiang-hua Wu, Xiao-long Fu, Min Fan, Guo-Liang Jiang, A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus, Investigational New Drugs, 2012, 30, 4, 1585

    CrossRef

  12. 12
    Alyssa M Master, Anirban Sen Gupta, EGF receptor-targeted nanocarriers for enhanced cancer treatment, Nanomedicine, 2012, 7, 12, 1895

    CrossRef

  13. 13
    Roshan James, Siddharth Vishwakarma, Indira V. Chivukula, Chetana Basavaraj, Ramakrishnan Melarkode, Enrique Montero, Pradip Nair, EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs, Cancer Medicine, 2012, 1, 2
  14. 14
    Lei Zhao, Li-Ru He, Mian Xi, Mu-Yan Cai, Jing-Xian Shen, Qiao-Qiao Li, Yi-Ji Liao, Dong Qian, Zi-Zhen Feng, Yi-Xin Zeng, Dan Xie, Meng-Zhong Liu, Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3, Journal of Translational Medicine, 2012, 10, 1, 249

    CrossRef

  15. 15
    Dirk Strumberg, Beate Schultheis, M. E. Scheulen, R. A. Hilger, J. Krauss, N. Marschner, F. Lordick, F. Bach, D. Reuter, L. Edler, K. Mross, Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer, Investigational New Drugs, 2012, 30, 3, 1138

    CrossRef

  16. 16
    Lei Zhao, Qiao-Qiao Li, Rui Zhang, Mian Xi, Yi-Ji Liao, Dong Qian, Li-Ru He, Yi-Xin Zeng, Dan Xie, Meng-Zhong Liu, The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin, Tumor Biology, 2012, 33, 4, 1115

    CrossRef

  17. 17
    Lorenzo Galluzzi, Erika Vacchelli, Wolf Hervé Fridman, Jérôme Galon, Catherine Sautès-Fridman, Eric Tartour, Jessica Zucman-Rossi, Laurence Zitvogel, Guido Kroemer, Trial Watch: Monoclonal antibodies in cancer therapy, OncoImmunology, 2012, 1, 1, 28

    CrossRef

  18. 18
    Benoit You, Anthony Brade, Joao M. Magalhaes, Lillian L. Siu, Amit Oza, Sonya Lovell, Lisa Wang, David W. Hedley, Leonardo V. Nicacio, Eric X. Chen, A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies, Investigational New Drugs, 2011, 29, 5, 996

    CrossRef

  19. 19
    Hye Jin Choi, Joo Hyuk Sohn, Chang Geol Lee, Hyo Sub Shim, Ik-Jae Lee, Woo Ick Yang, Ji Eun Kwon, Se Kyu Kim, Moo-Suk Park, Ju Hee Lee, Joo Hang Kim, A phase I study of nimotuzumab in combination with radiotherapy in stages IIB–IV non-small cell lung cancer unsuitable for radical therapy: Korean results, Lung Cancer, 2011, 71, 1, 55

    CrossRef

  20. 20
    Rolando Perez, Ernesto Moreno, Greta Garrido, Tania Crombet, EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects, Cancers, 2011, 3, 4, 2014

    CrossRef

  21. 21
    Gwyn Bebb, Colum Smith, Stewart Rorke, William Boland, Leonardo Nicacio, Ryan Sukhoo, Anthony Brade, Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy, Cancer Chemotherapy and Pharmacology, 2011, 67, 4, 837

    CrossRef

  22. 22
    Arlhee Diaz, Kalet Leon, Therapeutic Approaches to Target Cancer Stem Cells, Cancers, 2011, 3, 4, 3331

    CrossRef

  23. 23
    Yihang Wu, Mengjie Song, Zhuang Xin, Xiaoqing Zhang, Yu Zhang, Chunyu Wang, Suyi Li, Ning Gu, Ultra-small particles of iron oxide as peroxidase for immunohistochemical detection, Nanotechnology, 2011, 22, 22, 225703

    CrossRef

  24. 24
    Hye Kyung Shin, Mi-Sook Kim, Jae-Hoon Jeong, Combination Effect of Nimotuzumab with Radiation in Colorectal Cancer Cells, The Journal of the Korean Society for Therapeutic Radiology and Oncology, 2010, 28, 3, 147

    CrossRef

  25. 25
    Maija Hollmén, Klaus Elenius, Potential of ErbB4 antibodies for cancer therapy, Future Oncology, 2010, 6, 1, 37

    CrossRef

  26. 26
    Y. Diaz, A. Gonzalez, A. Lopez, R. Perez, A. M. Vazquez, E. Montero, Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma, Cancer Immunology, Immunotherapy, 2009, 58, 7, 1117

    CrossRef

  27. 27
    Arlhee Diaz, Ana E. Batista, Enrique Montero, Interferon-α Conditioned Sensitivity to an Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in a Human Lung Cancer Cell Line With Intermediate Expression of the Receptor, Journal of Interferon & Cytokine Research, 2009, 29, 8, 433

    CrossRef

  28. 28
    Jacques Bernier, Søren M. Bentzen, Jan B. Vermorken, Molecular therapy in head and neck oncology, Nature Reviews Clinical Oncology, 2009, 6, 5, 266

    CrossRef

  29. 29
    Peter J Bugelski, Ram Achuthanandam, Renold J Capocasale, George Treacy, Esther Bouman-Thio, Monoclonal antibody-induced cytokine-release syndrome, Expert Review of Clinical Immunology, 2009, 5, 5, 499

    CrossRef

  30. 30
    Soehartati GONDHOWIARDJO, Abdul MUTHALIB, Siti KHOTIMAH, Andhika RACHMAN, Nimotuzumab combined with radiotherapy reduces primary tumor and nodal volume in advanced undifferentiated nasopharyngeal carcinoma, Asia-Pacific Journal of Clinical Oncology, 2009, 5, 3
  31. 31
    Catherine Lam, Eric Bouffet, Ute Bartels, Nimotuzumab in pediatric glioma, Future Oncology, 2009, 5, 9, 1349

    CrossRef

  32. 32
    A Diaz Miqueli, J Rolff, M Lemm, I Fichtner, R Perez, E Montero, Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies, British Journal of Cancer, 2009, 100, 6, 950

    CrossRef

  33. 33
    Y Akashi, I Okamoto, T Iwasa, T Yoshida, M Suzuki, E Hatashita, Y Yamada, T Satoh, M Fukuoka, K Ono, K Nakagawa, Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status, British Journal of Cancer, 2008, 98, 4, 749

    CrossRef

  34. 34
    Elza Friedländer, Márk Barok, János Szöllősi, György Vereb, ErbB-directed immunotherapy: Antibodies in current practice and promising new agents, Immunology Letters, 2008, 116, 2, 126

    CrossRef

  35. 35
    Will R. Voelzke, W. Jeffery Petty, Glenn J. Lesser, Targeting the Epidermal Growth Factor Receptor in High-Grade Astrocytomas, Current Treatment Options in Oncology, 2008, 9, 1, 23

    CrossRef

  36. 36
    Arlhee Diaz Miqueli, Rances Blanco, Beatriz Garcia, Teresita Badia, Ana E. Batista, Ruby Alonso, Enrique Montero, Biological ActivityIn Vitroof Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies with Different Affinities, Hybridoma, 2007, 26, 6, 423

    CrossRef

  37. 37
    Nicolas Congy-Jolivet, Alicia Probst, Hervé Watier, Gilles Thibault, Recombinant therapeutic monoclonal antibodies: Mechanisms of action in relation to structural and functional duality, Critical Reviews in Oncology/Hematology, 2007, 64, 3, 226

    CrossRef

  38. 38
    Zhenping ZHU, Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives, Acta Pharmacologica Sinica, 2007, 28, 9
  39. 39
    Nicholas W. Choong, Ezra E.W. Cohen, Epidermal growth factor receptor directed therapy in head and neck cancer, Critical Reviews in Oncology/Hematology, 2006, 57, 1, 25

    CrossRef

  40. 40
    Shantaram Kamath, John K. Buolamwini, Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development, Medicinal Research Reviews, 2006, 26, 5
  41. 41
    Jochen Tuettenberg, Rainer Grobholz, Tobias Korn, Frederik Wenz, Ralf Erber, Peter Vajkoczy, Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme, Journal of Cancer Research and Clinical Oncology, 2005, 131, 1, 31

    CrossRef

  42. 42
    Sofia Agelaki, Vassilis Georgoulias, Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer, Expert Opinion on Emerging Drugs, 2005, 10, 4, 855

    CrossRef

  43. 43
    Helmout Modjtahedi, Molecular therapy of head and neck cancer, Cancer and Metastasis Reviews, 2005, 24, 1, 129

    CrossRef

  44. 44
    Nicholas W Choong, Patrick C Ma, Ravi Salgia, Therapeutic targeting of receptor tyrosine kinases in lung cancer, Expert Opinion on Therapeutic Targets, 2005, 9, 3, 533

    CrossRef

  45. 45
    Alicia Viloria-Petit, Enrique Rengifo-Calzado, Molecular Genetics, Liver Carcinoma, and Pancreatic Carcinoma, 2005,

    CrossRef

  46. 46
    Maria L. Amador, Manuel Hidalgo, Epidermal Growth Factor Receptor as a Therapeutic Target for the Treatment of Colorectal Cancer, Clinical Colorectal Cancer, 2004, 4, 1, 51

    CrossRef

  47. 47
    Carolyn I Sartor, Mechanisms of Disease: radiosensitization by epidermal growth factor receptor inhibitors, Nature Clinical Practice Oncology, 2004, 1, 2, 80

    CrossRef

  48. 48
    J.P. Oliva, T. Cruz, G. Pimentel, W. Quesada, R. Ortiz, M. Abreu, I. Sánchez, N. Díaz, R.P. Baum, Radioinmunolocalización de tumores de cabeza y cuello con un nuevo anticuerpo monoclonal contra el receptor del EGF. Resultados preliminares, Revista Española de Medicina Nuclear, 2004, 23, 4, 273

    CrossRef

  49. 49
    Philip Bonomi, Erlotinib: a new therapeutic approach for non-small cell lung cancer, Expert Opinion on Investigational Drugs, 2003, 12, 8, 1395

    CrossRef

  50. 50
    C Delbaldo, S Faivre, E Raymond, Les inhibiteurs des récepteurs de l’Epidermal Growth Factor (EGF), La Revue de Médecine Interne, 2003, 24, 6, 372

    CrossRef

  51. 51
    Tania Crombet, Leonel Torres, Elia Neninger, Mauricio Catalá, María E. Solano, Alejandro Perera, Olga Torres, Normando Iznaga, Franz Torres, Rolando Pérez, Agustín Lage, Pharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients With Advanced Epithelial-Derived Cancer, Journal of Immunotherapy, 2003, 26, 2, 139

    CrossRef